Physician profile
Jonathan Nestor
NPI 1154318533
$2,581.93
in general payments reported to CMS, 2019-2025
25 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $108 · 2021: $40.96 · 2022: $391 · 2023: $588 · 2024: $789 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,707 · Education: $56.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.31 |
| Education | $56.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $768.67 | 2019-2025 | Lokelma, Farxiga, Fasenra |
| Akebia Therapeutics INC | $259.89 | 2019-2024 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $246.38 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $219.18 | 2019-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.54 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $110.80 | 2023-2025 | Filspari |
| Vifor Pharma, INC. | $106.96 | 2019-2023 | Veltassa |
| Glaxosmithkline, LLC. | $96.79 | 2020-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $86.22 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $75.67 | 2023-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $66.30 | 2024-2025 | |
| Lilly USA, LLC | $49.37 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $48.51 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $44.51 | 2022-2024 | Lupkynis |
| Regeneron Healthcare Solutions, INC. | $42.10 | 2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $33.69 | 2020-2023 | Injectafer |
| Horizon Therapeutics Plc | $31.89 | 2022-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $29.19 | 2019 | |
| Ani Pharmaceuticals, INC. | $27.94 | 2022-2025 | Purified Cortrophin Gel |
| Renalytix Ai, INC. | $24.71 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Pharmacosmos Therapeutics INC. | $20.10 | 2024 | Monoferric |
| Alexion Pharmaceuticals, INC. | $18.85 | 2022 | |
| Opko Pharmaceuticals, LLC | $18.28 | 2021 | |
| Scpharmaceuticals INC. | $18.04 | 2024 | |
| Grifols USA, LLC | $17.35 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Nestor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.